10-Q 1 rvnc-20240331.htm 10-Q rvnc-20240331
000147929012/312024Q1FALSE0.0308804xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesrvnc:segmentrvnc:option_to_extend_lease_termxbrli:purervnc:trading_dayrvnc:patent00014792902024-01-012024-03-3100014792902024-04-3000014792902024-03-3100014792902023-12-310001479290us-gaap:ProductMember2024-01-012024-03-310001479290us-gaap:ProductMember2023-01-012023-03-310001479290rvnc:CollaborationRevenueMember2024-01-012024-03-310001479290rvnc:CollaborationRevenueMember2023-01-012023-03-3100014792902023-01-012023-03-310001479290us-gaap:PreferredStockMember2024-03-310001479290us-gaap:PreferredStockMember2023-12-310001479290us-gaap:PreferredStockMember2022-12-310001479290us-gaap:PreferredStockMember2023-03-310001479290us-gaap:CommonStockMember2023-12-310001479290us-gaap:CommonStockMember2022-12-310001479290us-gaap:CommonStockMemberrvnc:FollowOnOfferingMember2024-01-012024-03-310001479290us-gaap:CommonStockMemberrvnc:FollowOnOfferingMember2023-01-012023-03-310001479290us-gaap:CommonStockMember2024-01-012024-03-310001479290us-gaap:CommonStockMember2023-01-012023-03-310001479290us-gaap:CommonStockMember2024-03-310001479290us-gaap:CommonStockMember2023-03-310001479290us-gaap:AdditionalPaidInCapitalMember2023-12-310001479290us-gaap:AdditionalPaidInCapitalMember2022-12-310001479290us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001479290us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001479290us-gaap:AdditionalPaidInCapitalMember2024-03-310001479290us-gaap:AdditionalPaidInCapitalMember2023-03-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001479290us-gaap:RetainedEarningsMember2023-12-310001479290us-gaap:RetainedEarningsMember2022-12-310001479290us-gaap:RetainedEarningsMember2024-01-012024-03-310001479290us-gaap:RetainedEarningsMember2023-01-012023-03-310001479290us-gaap:RetainedEarningsMember2024-03-310001479290us-gaap:RetainedEarningsMember2023-03-3100014792902023-03-3100014792902022-12-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberrvnc:FintechPlatformMember2024-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberrvnc:FintechPlatformMember2023-12-310001479290rvnc:AtTheMarketOffering2022PlanMember2024-01-012024-03-310001479290rvnc:FintechPlatformMember2024-01-012024-03-310001479290rvnc:FintechPlatformMember2024-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberus-gaap:EmployeeSeveranceMemberrvnc:FintechPlatformMember2024-01-012024-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberrvnc:FintechPlatformMember2024-01-012024-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberus-gaap:ServiceMemberrvnc:FintechPlatformMember2024-01-012024-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberus-gaap:ServiceMemberrvnc:FintechPlatformMember2023-01-012023-03-310001479290us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberrvnc:FintechPlatformMember2023-01-012023-03-310001479290rvnc:ServiceSegmentMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001479290rvnc:ServiceSegmentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001479290rvnc:ServiceSegmentMember2024-01-012024-03-310001479290us-gaap:DiscontinuedOperationsHeldforsaleMemberrvnc:FintechPlatformMember2023-01-012023-03-310001479290rvnc:RHACollectionOfDermalFillersMember2024-01-012024-03-310001479290rvnc:RHACollectionOfDermalFillersMember2023-01-012023-03-310001479290rvnc:DAXXIFYMember2024-01-012024-03-310001479290rvnc:DAXXIFYMember2023-01-012023-03-310001479290us-gaap:ProductMember2024-03-310001479290us-gaap:ProductMember2023-12-310001479290rvnc:ViatrisMember2024-03-310001479290rvnc:ViatrisMember2024-01-012024-03-310001479290rvnc:ViatrisMember2024-01-012024-03-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2024-03-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2024-01-012024-03-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2023-01-012023-03-310001479290rvnc:ViatrisMember2024-03-310001479290rvnc:ViatrisMember2023-12-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2023-12-310001479290rvnc:CollaborationCustomersMember2024-03-310001479290rvnc:CollaborationCustomersMember2023-12-310001479290us-gaap:USTreasurySecuritiesMember2024-03-310001479290us-gaap:USTreasurySecuritiesMember2023-12-310001479290us-gaap:CommercialPaperMember2024-03-310001479290us-gaap:CommercialPaperMember2023-12-310001479290us-gaap:MoneyMarketFundsMember2024-03-310001479290us-gaap:MoneyMarketFundsMember2023-12-310001479290us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001479290us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001479290us-gaap:CashEquivalentsMember2024-03-310001479290us-gaap:CashEquivalentsMember2023-12-310001479290us-gaap:OtherCurrentAssetsMember2024-03-310001479290us-gaap:OtherCurrentAssetsMember2023-12-310001479290us-gaap:DistributionRightsMember2024-03-310001479290us-gaap:DistributionRightsMember2023-12-310001479290us-gaap:SoftwareDevelopmentMember2023-12-310001479290us-gaap:DevelopedTechnologyRightsMember2023-12-310001479290us-gaap:CustomerRelatedIntangibleAssetsMember2023-12-310001479290us-gaap:SoftwareDevelopmentMember2024-01-012024-03-310001479290srt:ScenarioPreviouslyReportedMember2024-01-012024-03-310001479290srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-01-012024-03-310001479290srt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001479290srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-01-012023-03-310001479290srt:MinimumMember2024-03-310001479290srt:MaximumMember2024-03-310001479290us-gaap:SubsequentEventMember2024-04-300001479290rvnc:ABPSFillAndFinishLineLeaseMember2024-03-310001479290rvnc:OtherOperatingLeasesMember2024-03-3100014792902021-04-012021-04-300001479290rvnc:PCISupplyAgreementMember2021-04-012021-04-300001479290rvnc:PCISupplyAgreementMember2024-03-310001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMember2024-03-310001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMember2023-12-310001479290us-gaap:ConvertibleDebtMember2024-03-310001479290us-gaap:ConvertibleDebtMember2023-12-310001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMember2020-02-290001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMember2020-02-012020-02-290001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMemberrvnc:DebtConversionTermsOneMember2020-02-012020-02-290001479290us-gaap:ConvertibleDebtMemberrvnc:TwentyTwentySevenNotesMemberrvnc:DebtConversionTermsTwoMember2020-02-012020-02-2900014792902020-02-012020-02-2900014792902020-02-2900014792902020-02-102020-02-100001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2022-03-310001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2023-08-300001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2023-08-310001479290us-gaap:NotesPayableOtherPayablesMemberrvnc:NotePurchaseAgreementMember2023-08-310001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2023-08-310001479290srt:MaximumMemberrvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMember2023-08-310001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2022-06-300001479290us-gaap:NotesPayableOtherPayablesMemberrvnc:NotePurchaseAgreementMember2022-06-300001479290rvnc:SecuredOvernightFinanceRateSOFRMemberrvnc:NotePurchaseAgreementMembersrt:MinimumMember2022-03-012022-03-310001479290srt:MaximumMemberrvnc:SecuredOvernightFinanceRateSOFRMemberrvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMember2022-03-012022-03-310001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberrvnc:DebtInstrumentPrincipalAmortizationPeriodOneMember2022-03-180001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberrvnc:DebtInstrumentPrincipalAmortizationPeriodTwoMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2022-03-180001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberrvnc:DebtInstrumentPrincipalAmortizationPeriodThreeMember2022-03-180001479290rvnc:NotePurchaseAgreementMemberus-gaap:NotesPayableOtherPayablesMemberrvnc:DebtInstrumentPrincipalAmortizationPeriodFourMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2022-03-180001479290us-gaap:NotesPayableOtherPayablesMemberrvnc:TwentyTwentySevenNotesMember2022-03-180001479290us-gaap:NotesPayableOtherPayablesMemberrvnc:NotePurchaseAgreementMember2022-03-180001479290us-gaap:NotesPayableOtherPayablesMemberrvnc:NotePurchaseAgreementMember2022-03-182022-03-180001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMember2024-01-010001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMemberrvnc:StockAwardMember2024-01-012024-03-310001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMember2024-03-310001479290rvnc:TwoThousandAndFourteenInducementPlanMember2024-01-012024-03-310001479290rvnc:TwoThousandAndFourteenInducementPlanMember2024-03-310001479290rvnc:A2017EquityIncentivePlanHintMDPlanMember2024-01-012024-03-310001479290rvnc:A2017EquityIncentivePlanHintMDPlanMember2024-03-310001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2024-01-010001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2024-03-310001479290us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-03-310001479290us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-03-310001479290us-gaap:PhantomShareUnitsPSUsMember2024-01-012024-03-310001479290us-gaap:PhantomShareUnitsPSUsMember2023-01-012023-03-310001479290us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001479290us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001479290us-gaap:RestrictedStockMember2024-01-012024-03-310001479290us-gaap:RestrictedStockMember2023-01-012023-03-310001479290us-gaap:EmployeeStockOptionMemberrvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2024-01-012024-03-310001479290us-gaap:EmployeeStockOptionMemberrvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2023-01-012023-03-310001479290rvnc:FollowOnOfferingMember2023-03-012023-03-310001479290rvnc:FollowOnOfferingMember2023-03-310001479290rvnc:ChiefExecutiveOfficerAndDirectorMemberrvnc:FollowOnOfferingMember2023-03-012023-03-310001479290rvnc:ChiefExecutiveOfficerAndDirectorMemberrvnc:FollowOnOfferingMember2023-03-310001479290rvnc:AtTheMarketOffering2022PlanMember2022-05-102022-05-100001479290rvnc:AtTheMarketOffering2022PlanMember2023-01-012023-12-310001479290srt:WeightedAverageMemberrvnc:AtTheMarketOffering2022PlanMember2023-12-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:ScenarioPreviouslyReportedMember2024-01-012024-03-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-01-012024-03-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001479290srt:ScenarioPreviouslyReportedMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001479290us-gaap:ResearchAndDevelopmentExpenseMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-01-012024-03-310001479290us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-01-012023-03-310001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001479290srt:ScenarioPreviouslyReportedMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001479290us-gaap:ResearchAndDevelopmentExpenseMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-01-012023-03-310001479290us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001479290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001479290us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001479290us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001479290rvnc:TeoxaneAgreementMember2020-01-012020-01-310001479290rvnc:TeoxaneAgreementMember2020-09-012020-09-300001479290rvnc:TeoxaneAgreementMember2024-03-310001479290rvnc:BotulinumToxinResearchAssociatesInc.Member2024-03-3100014792902022-12-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___ to ___
Commission File No. 001-36297
Revance Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware77-0551645
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)

1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
(Address, including zip code, of principal executive offices)

(615) 724-7755
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareRVNCNasdaq Global Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerEmerging growth company
Non-accelerated filerSmaller reporting company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes     No  ý
Number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of April 30, 2024: 104,448,502


Table of Contents

Page
PART I. FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
PART II. OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.




DEFINED TERMS
Unless expressly indicated or the context requires otherwise, the terms “Revance,” “Company,” “we,” “us,” and “our,” in this Quarterly Report on Form 10-Q (this “Report”) refer to Revance Therapeutics, Inc., a Delaware corporation, and, where appropriate, its wholly-owned subsidiaries. We also have used several other terms in this Report, the condensed consolidated financial statements and accompanying notes included herein, most of which are explained or defined below.
“2014 EIP” means the Company’s 2014 Equity Incentive Plan.
“2014 ESPP” means the Company’s 2014 Employee Stock Purchase Plan.
“2014 IN” means the Company’s 2014 Inducement Plan.
“2022 ATM Agreement” means the Sales Agreement by and between Revance and Cowen, dated May 10, 2022.
“2027 Notes” means Revance’s 1.75% Convertible Senior Notes due 2027.
“ABPS” means Ajinomoto Althea, Inc., doing business as Ajinomoto Bio-Pharma Services, a contract development and manufacturing organization.
“ABPS Services Agreement” means the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement by and between the Company and ABPS, dated March 14, 2017, as amended on December 18, 2020.
“Adjusted Three-Month LIBOR” has the meaning set forth in the Note Purchase Agreement.
“Allergan” means Allergan, Inc.
“Amortization Trigger” has the meaning set forth in the Note Purchase Agreement.
“ASC” means the Accounting Standards Codification as set forth by the Financial Accounting Standards Board.
“ASU” means Accounting Standards Update issued by the FASB.
“Athyrium” means Athyrium Buffalo LP.
“ATM” means at-the-market offering program.
“BTRX” means Botulinum Toxin Research Associates, Inc.
“Consolidated Teoxane Distribution Net Product Sales” has the meaning set forth in the Note Purchase Agreement.
“consumers” means the patients of our aesthetic practice customers.
“Cowen” means Cowen and Company, LLC.
“CROs” means contract research organizations.
“DAXXIFY® means (DaxibotulinumtoxinA-lanm) for injection.
“DAXXIFY® GL Approval” means the FDA approval in September 2022, of DAXXIFY® in the United States for the temporary improvement of moderate to severe glabellar lines in adults.
“DAXXIFY® GL Approval PSUs” means performance stock units that vested on the 6-month anniversary of the date of DAXXIFY® GL Approval.
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.
“FASB” means the Financial Accounting Standards Board.
“FDA” means the United States Food and Drug Administration.
“Fintech Platform” means OPUL® and the HintMD Platform.
i


“First Amendment” means the first amendment to the Note Purchase Agreement, by and among the Company, HintMD and Athyrium, dated August 8, 2023.
“First Tranche” means the Notes Payable issued to the Purchasers in an aggregate principal amount of $100.0 million on March 18, 2022.
“Fosun” means Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
“Fosun License Agreement” means the License Agreement by and between Revance and Fosun, dated December 4, 2018, as amended on February 15, 2020.
“Fosun Territory” means mainland China, Hong Kong and Macau.
“FY2023 Form 10-K” means our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 28, 2024.
“HintMD” means Hint, Inc., our wholly owned subsidiary.
“HintMD Plan” means the Hint, Inc. 2017 Equity Incentive Plan.
“HintMD Platform” means the legacy HintMD fintech platform.
“Indenture” means the indenture, by and between Revance and U.S. Bank National Association, as trustee, dated February 14, 2020.
“injector” means a professional licensed to inject our Products, including physicians.
“Maturity Date” means September 18, 2026, the maturity date of the Notes Payable set forth in the Note Purchase Agreement.
“neuromodulator” means injectable botulinum toxins and neurotoxins.
“NMPA” means China's National Medical Products Administration.
“Note Purchase Agreement” means the note purchase agreement by and between Revance; Athyrium, as administrative agent; the Purchasers, including Athyrium; and HintMD, as a guarantor, dated March 18, 2022.
“Notes Payable” means notes payable by Revance pursuant to the Note Purchase Agreement.
“NPA Effective Date” means the effective date of the Note Purchase Agreement, March 18, 2022.
“onabotulinumtoxinA biosimilar” means a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®.
“option counterparties” means capped call transactions with a purchaser and another financial institution.
“OPUL® means the OPUL® Relational Commerce Platform.
“PAS” means prior approval supplement.
“PCI” means PCI Pharma Services, formerly known as Lyophilization Services of New England, Inc., which was acquired by PCI in December 2021.
“PCI Supply Agreement” means the Commercial Supply Agreement by and between Revance and PCI, dated April 6, 2021.
“Products” means DAXXIFY® and the RHA Collection® of dermal fillers.
“PSAs” means a performance stock award.
“PSUs” means a performance stock unit.
“Purchasers” means Athyrium and its successors and assigns.
ii


“RHA® Collection of dermal fillers” means RHA® 2, RHA® 3 and RHA® 4, which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds; and RHA® Redensity.
“RHA® Pipeline Products” means future hyaluronic acid filler advancements and products by Teoxane.
“RHA® Redensity” means a dermal filler, which has been approved by the FDA for the treatment of moderate to severe dynamic perioral rhytids (lip lines).
“RSAs” means restricted stock awards.
“RSUs” means restricted stock units.
“SEC” means the U.S. Securities and Exchange Commission.
“Second Tranche” means the Notes Payable issued to the Purchasers in an aggregate principal amount of $50.0 million on August 28, 2023.
“Securities Act” means the U.S. Securities Act of 1933, as amended.
“Services” means the Fintech Platform business.
“Service Segment” means the business that includes the development and commercialization of the Fintech Platform.
“Third Tranche” means the uncommitted tranche of additional Notes Payable in an aggregate amount of up to $150.0 million, which was available until March 31, 2024, subject to the satisfaction of certain conditions set forth in the Note Purchase Agreement.
“Teoxane” means Teoxane SA.
“Teoxane Agreement” means the exclusive distribution agreement by and between Revance and Teoxane, dated January 10, 2020, as amended on September 30, 2020, December 22, 2020 and December 22, 2022.
“U.S. GAAP” means U.S. generally accepted accounting principles.
“Viatris” means Viatris Inc., formerly known as Mylan Ireland Ltd.
“Viatris Agreement” means the Collaboration and License Agreement by Revance and Viatris, dated February 28, 2018, as amended on August 22, 2019.
“Viatris Territory” means world-wide (excluding Japan).
“Zero-cost Inventory” means DAXXIFY® inventory produced prior to the DAXXIFY® GL Approval in early September 2022, for which the related manufacturing costs were incurred and expensed to research and development expense prior to the FDA approval.
Revance®, the Revance logos, DAXXIFY®, OPUL® and other trademarks or service marks of Revance appearing in this Report are the property of Revance. This Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.
iii

PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements (Unaudited)
1


REVANCE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
 March 31, 2024December 31,
 20242023
ASSETS
CURRENT ASSETS
Cash and cash equivalents$132,609 $137,329 
Restricted cash, current550 550 
Short-term investments144,463 116,586 
Accounts receivable, net29,887 27,660 
Inventories50,280 45,579 
Prepaid expenses and other current assets9,287 9,308 
Current assets of discontinued operations2,610 1,853 
Total current assets369,686 338,865 
Property and equipment, net17,505 17,225 
Intangible assets, net8,725 9,270 
Operating lease right-of-use assets70,245 53,167 
Finance lease right-of-use asset 19,815 
Restricted cash, non-current5,895 5,995 
Finance lease prepaid expense35,846 32,383 
Other non-current assets217 321 
Non-current assets of discontinued operations 1,413 
TOTAL ASSETS$508,119 $478,454 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable$5,276 $13,554 
Accruals and other current liabilities40,311 52,863 
Deferred revenue, current9,784 10,737 
Operating lease liabilities, current7,126 5,703 
Finance lease liability, current 2,651 
Debt, current5,000 2,500 
Current liabilities of discontinued operations1,406 1,216 
Total current liabilities68,903 89,224 
Debt, non-current424,838 426,595 
Deferred revenue, non-current71,403 70,419 
Operating lease liabilities, non-current38,813 40,985 
Other non-current liabilities2,835 2,835 
TOTAL LIABILITIES606,792 630,058 
Commitments and Contingencies (Note 12)
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2024 and December 31, 2023
  
Common stock, par value $0.001 per share — 190,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 104,409,798 and 87,962,765 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
104 88 
Additional paid-in capital2,032,760 1,926,654 
Accumulated other comprehensive gain (loss)(25)14 
Accumulated deficit(2,131,512)(2,078,360)
TOTAL STOCKHOLDERS’ DEFICIT(98,673)(151,604)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT$508,119 $478,454 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2

REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
 
 Three Months Ended March 31,
 20242023
Revenue:
Product revenue, net$51,719 $45,658 
Collaboration revenue217 116 
Total revenue, net51,936 45,774 
Operating expenses:
Cost of product revenue (exclusive of amortization)14,911 12,487 
Selling, general and administrative68,914 61,920 
Research and development14,393 17,532 
Amortization545 545 
Total operating expenses98,763 92,484 
Loss from continuing operations(46,827)(46,710)
Interest income2,996 2,970 
Interest expense(5,256)(4,497)
Other expense, net(438)(234)
Net loss from continuing operations(49,525)(48,471)
Net loss from discontinued operations(3,627)(11,322)
Total net loss(53,152)(59,793)
Unrealized gain (loss)(39)249 
Comprehensive loss$(53,191)$(59,544)
Basic and diluted net loss per share:
Continuing operations$(0.54)$(0.60)
Discontinued operations(0.04)(0.14)
Total net loss per basic and diluted share$(0.58)$(0.74)
Basic and diluted weighted-average number of shares used in computing net loss per share91,919,018 81,134,111 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share and per share amounts)
(Unaudited)
 
Three Months Ended March 31,
20242023
SharesAmountSharesAmount
Preferred Stock $  $ 
Common Stock
Balance — Beginning of period87,962,765 88 82,385,810 82 
Issuance of common stock in connection with follow-on offering16,000,000 16   
Issuance of common stock related to stock awards, net of cancellation497,844 — 1,188,248 1 
Issuance of common stock upon exercise of stock options7,722  562,039 1 
Shares withheld related to net settlement of stock awards(58,533) (118,889)— 
Balance — End of period104,409,798 104 84,017,208 84 
Additional Paid-In Capital
Balance — Beginning of period— 1,926,654 — 1,767,266 
Issuance of common stock in connection with follow-on offering, net of underwriting discounts and offering costs— 97,110 —  
Issuance of common stock upon exercise of stock options— 20 — 9,481 
Shares withheld related to net settlement of stock awards— (402)— (3,730)
Issuance of common stock related to stock awards, net of cancellation—  — (1)
Stock-based compensation— 9,378 — 14,489 
Other—  — 30 
Balance — End of period— 2,032,760 — 1,787,535 
Other Accumulated Comprehensive Gain (loss)
Balance — Beginning of period— 14 — (374)
Unrealized gain (loss)— (39)— 249 
Balance — End of period— (25)— (125)
Accumulated Deficit
Balance — Beginning of period— (2,078,360)— (1,754,374)
Net loss— (53,152)— (59,793)
Balance — End of period— (2,131,512)— (1,814,167)
Total Stockholders’ Deficit104,409,798 $(98,673)84,017,208 $(26,673)
    
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited) 
 Three Months Ended March 31,
 20242023
CASH FLOWS FROM OPERATING ACTIVITIES
Total net loss$(53,152)$(59,793)
Adjustments to reconcile total net loss to net cash used in operating activities:
Stock-based compensation8,990 13,082 
Depreciation and amortization1,981 4,301 
Amortization of debt discount and debt issuance costs757 517 
Amortization of discount on investments(1,361)(1,750)
Amortization of finance lease right-of-use asset 2,317 
Other non-cash operating activities(19)315 
Changes in operating assets and liabilities:
Accounts receivable(2,210)(4,034)
Inventories(2,113)(7,639)
Prepaid expenses and other current assets123 (1,296)
Lease right-of-use assets621 (22,411)
Other non-current assets90 (417)
Accounts payable(6,835)5,095 
Accruals and other liabilities(11,884)(23,311)
Deferred revenue31 1,616 
Lease liabilities(958)22,558 
Other non-current liabilities 1,350 
Net cash used in operating activities(65,939)(69,500)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments(73,035)(29,294)
Finance lease prepayments(3,462) 
Purchases of property and equipment(1,712)(870)
Proceeds from maturities of investments46,500 125,480 
Net cash provided by (used in) investing activities(31,709)95,316 
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock in connection with follow-on offering, net of underwriting discounts 97,626  
Proceeds from the exercise of stock options20 9,481 
Principal payments on finance lease obligations(4,227)(2,486)
Taxes paid related to net settlement of stock awards(402)(3,730)
Payment of offering costs(189) 
Net cash provided by financing activities92,828 3,265 
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH(4,820)29,081 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period(1)
144,749 115,017 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period(1)
$139,929 $144,098 
(1)Cash, cash equivalents, and restricted cash included $0.9 million of restricted cash classified as current assets of discontinued operations as of March 31, 2024, and non-current assets of discontinued operations as of December 31, 2023 on condensed consolidated balance sheets.


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. The Company and Summary of Significant Accounting Policies
Overview
Revance is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY® in China.
Liquidity and Financial Condition
We are not profitable and have incurred losses in each year since our inception. For the three months ended March 31, 2024, we had a total net loss of $53.2 million and an accumulated deficit of $2.1 billion. Although we generate revenue from the sale of our Products, we expect to continue to incur GAAP operating losses for the foreseeable future.
As of March 31, 2024, we had a working capital surplus of $300.8 million and capital resources of $277.1 million consisting of cash, cash equivalents, and short-term investments. To date, we have funded our operations primarily through the sale of common stock, convertible senior notes, sales of Products, proceeds from notes issued pursuant to the Note Purchase Agreement, and payments received from collaboration arrangements. We also have a remaining capacity to sell up to $47.2 million of our common stock under the 2022 ATM Agreement as of March 31, 2024. We believe that our existing capital resources will be sufficient to fund the operating plan through at least the next 12 months following the issuance of the condensed consolidated financial statements in this Report.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented.
Our condensed consolidated balance sheet for the year ended December 31, 2023 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2024, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our FY2023 Form 10-K.
Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated.
The requirements for reporting the exit of the Fintech Platform business (Note 2) as a discontinued operation were met in the first quarter of 2024. As a result, the Fintech Platform business is presented in the condensed consolidated statement of operations and condensed consolidated balance sheet as discontinued operations for all periods presented. Unless indicated otherwise, the information in the notes to the condensed consolidated financial statements relates to continuing operations. The Company operates under one reportable segment as a result of discontinuing the Service Segment.
Use of Estimates & Risks and Uncertainties
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the
6

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. U.S. GAAP requires us to make estimates and judgments in several areas, including, but not limited to, the incremental borrowing rate used to measure lease liabilities, the recoverability of long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, valuation and assumptions underlying stock-based compensation and other equity instruments, and income taxes.
As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.
Significant Accounting Policies
There have been no material changes to our significant accounting policies from our FY2023 Form 10-K.
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This standard requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. We are currently evaluating the impact of adopting ASU 2023-07.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740). ASU 2023-09 improves reporting for income taxes, primarily by requiring disclosure of specific categories in the tax rate reconciliation and providing additional annual information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 also require additional annual information regarding income taxes paid, as well as other additional disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, early adoption is permitted. We are currently evaluating the effect the amendments in ASU 2023-09 will have on our tax disclosures.
In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. In addition, the rules will require registrants to present certain climate-related financial metrics in the audited financial statements. These requirements are effective for the Company in various fiscal years, starting with its fiscal year beginning January 1, 2025. Disclosures will be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. In April 2024, the SEC determined to voluntarily stay the final rules pending the outcome of certain legal challenges. We are currently evaluating the impact of these final rules on future financial reporting requirements and related disclosures.
2. Exit of the Fintech Platform Business
In September 2023, we commenced a plan to exit the Fintech Platform business as the costs and resources required to support the Fintech Platform no longer aligned with the Company’s capital allocation priorities. The exit and restructuring activities included elimination of Fintech Platform personnel, the termination of Fintech Platform research and development activities and an elimination of outside services expenses related to the Fintech Platform. Based on such plan, substantially all
7

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
payment processing activities for Fintech Platform customers ended on January 31, 2024 and we substantially completed the remaining activities to wind-down the Fintech Platform operations as of March 31, 2024.
In accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations, the substantial completion of exit of the Fintech Platform business represents a strategic shift that has a major effect on the Company’s operations and financial results. The Fintech Platform business was historically reported as the Service Segment. As a result, the results of our Fintech Platform business have been reflected as discontinued operations in our condensed consolidated financial statements. Our condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive loss includes reclassification of certain prior year figures to conform to the current period presentation.
Details of assets and liabilities from discontinued operations are as follows:
 
March 31,
December 31,
(in thousands)20242023
Restricted cash, current
$875$
Accounts receivable, net
16
Prepaid expenses and other current assets
1,7351,837
Total current assets of discontinued operations
$2,610$1,853
Intangible assets, net
$$538
Restricted cash, non-current
875
Total non-currents assets of discontinued operations
$$1,413
Accounts payable
$$255
Accruals and other current liabilities
1,406961
Total current liabilities of discontinued operations (1)
$1,406$1,216
(1)Amount represents severance and personnel liabilities related to the exit of the Fintech Platform business. We substantially completed the restructuring activities as of March 31, 2024. Prior to the issuance of the condensed consolidated financial statements in this Report, $0.9 million was paid and the remaining $0.5 million will be paid over time through the third quarter of 2024. A summary of severance and personnel liabilities related to the exit of the Fintech Platform business, included within current liabilities of discontinued operations on the consolidated balance sheet, is as follows:
(in thousands)
Balance on December 31, 2023$917 
Severance and other personnel costs766 
Cash payments during the period(277)
Balance on March 31, 2024
$1,406 
8

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Details of loss from discontinued operations are as follows:
 Three Months Ended March 31,
(in thousands)20242023
Service revenue$426 $3,557 
Operating expenses:
Cost of service revenue (exclusive of amortization)316 3,684 
Selling, general and administrative (1)
2,073 4,091 
Research and development (1)
1,664 5,645 
Amortization 1,459 
Net loss from discontinued operations$(3,627)$(11,322)
(1)The restructuring charges are included in the results of discontinued operations for the periods of our condensed consolidated financial statements presented in this Report. A summary of our restructuring charges included within our consolidated statement of operations for the three months ended March 31, 2024 were as follows:
(in thousands)
Research and development$412 
Selling, general and administrative
354 
Total restructuring charges
$766 
As of March 31, 2024, we have recorded total restructuring charges of $3.6 million and impairment charges of $93.2 million in connection with the exit of the Fintech Platform business.
The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. Significant non-cash activities related to discontinued operations are as follows:
Three Months Ended March 31,
20242023
Operating activities:
Stock-based compensation$227 $2,130 
Depreciation and amortization$538 $2,104 

3. Revenue
Our revenue is primarily generated from U.S. customers. Our product revenue is generated by transferring goods at a point in time and our collaboration revenue is generated over time.
Product Revenue, net
Our product revenue, net breakdown is summarized below:
Three Months Ended March 31,
(in thousands)20242023
Product:
RHA® Collection of dermal fillers
$29,570 $30,280 
DAXXIFY®
22,149 15,378 
Total product revenue, net
$51,719 $45,658 
9

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Accounts receivable and contract liabilities from contracts with our product customers are as follows:
March 31,December 31,
(in thousands)20242023
Accounts receivable:
Accounts receivable, gross
$30,968 $27,975 
Allowance for doubtful accounts
(1,081)(950)
Total accounts receivable, net$29,887 $27,025 
Contract liabilities:
Deferred revenue, current$455 $884 
Total contract liabilities$455 $884 
Collaboration Revenue
Viatris Agreement
Agreement Terms
We entered into the Viatris Agreement in February 2018, pursuant to which we are collaborating with Viatris exclusively, in the Viatris Territory, to develop, manufacture, and commercialize an onabotulinumtoxinA biosimilar.
Viatris has paid us an aggregate of $60 million in non-refundable upfront and milestone fees as of March 31, 2024, and the agreement provides for additional remaining contingent payments of up to $70 million in the aggregate, upon the achievement of certain clinical and regulatory milestones and of specified, tiered sales milestones of up to $225 million. The payments do not represent a financing component for the transfer of goods or services. In addition, Viatris is required to pay us low to mid-double digit royalties on any sales of the biosimilar in the U.S., mid-double digit royalties on any sales in Europe, and high single digit royalties on any sales in other ex-U.S. Viatris territories. However, we have agreed to waive royalties for U.S. sales, up to a maximum of $50 million in annual sales, during the first approximately four years after commercialization to defray launch costs.
Revenue Recognition
We estimated the transaction price for the Viatris Agreement using the most likely amount method within the scope of ASC 606. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Viatris. Other than the upfront payment, all other milestones and consideration we may earn under the Viatris Agreement are subject to uncertainties related to development achievements, Viatris’ rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. At the end of each reporting period, we re-evaluate the probability of achievement of each such milestone and any related constraint, and if necessary, adjust our estimates of the overall transaction price. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Viatris Agreement. As of March 31, 2024, the transaction price allocated to the unfulfilled performance obligations was $31.0 million.
We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development services to be provided for the development period. For revenue recognition purposes, the development period has an estimated accounting program end date of 2027. It is possible that this period will change and is assessed at each reporting date. ASC Topic 606, Revenue from Contracts with Customers (ASC 606) requires that an entity include a constraint on the amount of variable consideration included in the transaction price. Variable consideration is
10

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
considered “constrained” if there is a potential for significant reversal of cumulative revenue recognized. As part of the constraint evaluation, we considered numerous factors, including a shift in certain responsibilities between the two parties which would result in changes to the net cost sharing payments and the total project budget, for which outcomes are difficult to predict as of the date of this Report. We will continue to evaluate the variable transaction price and related revenue recognition in each reporting period and as the above uncertainties are resolved or other changes in circumstances occur. For the three months ended March 31, 2024, we recognized revenue related to development services under the Viatris Agreement of $0.2 million. For the three months ended March 31, 2023, no collaboration revenue is recognized from the biosimilar program.
Fosun License Agreement
Agreement Terms
In December 2018, we entered into the Fosun License Agreement with Fosun, whereby we granted Fosun the exclusive rights to develop and commercialize DaxibotulinumtoxinA for Injection in the Fosun Territory and certain sublicense rights.
As of March 31, 2024, Fosun has paid us non-refundable upfront and other payments totaling $41.0 million before foreign withholding taxes. We are also eligible to receive (i) additional remaining contingent payments of up to $219.5 million upon the achievement of certain milestones, and (ii) tiered royalty payments in low double digits to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory.
Revenue Recognition
We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of March 31, 2024, the transaction price allocated to unfulfilled performance obligation is $41.0 million. For the three months ended March 31, 2024, no revenue was recognized from the Fosun License Agreement. For the three months ended March 31, 2023, we recognized revenue of $0.1 million related to the Fosun License Agreement.
Accounts receivable and contract liabilities from contracts with our collaboration customers are as follows:
March 31,December 31,
(in thousands)20242023
Accounts receivable:
Accounts receivable — Viatris
$ $631 
Accounts receivable — Fosun
 4 
Total accounts receivable
$ $635 
Contract liabilities:
Deferred revenue, current — Viatris$9,329 $9,853 
Total contract liabilities, current$9,329 $9,853 
Deferred revenue, non-current — Viatris$30,428 $29,444 
Deferred revenue, non-current — Fosun40,975 40,975 
Total contract liabilities, non-current$71,403 $70,419 
11

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Changes in our contract liabilities from contracts with our collaboration revenue customers for the three months ended March 31, 2024 are as follows:
(in thousands)
Balance on December 31, 2023$80,272 
Revenue recognized(217)
Billings and adjustments, net677 
Balance on March 31, 2024$80,732 

4. Cash Equivalents and Short-Term Investments
The following table is a summary of our cash equivalents and short-term investments:
March 31, 2024December 31, 2023
in thousandsAdjusted CostUnrealized GainUnrealized LossFair ValueAdjusted CostUnrealized GainUnrealized LossFair Value
U.S. treasury securities$147,818 $ $(4)$147,814 $133,168 $30 $ $133,198 
Commercial paper56,508  (22)56,486 49,433  (15)49,418 
Money market funds41,809   41,809 39,280   39,280 
U.S. government agency obligations8,430 1  8,431 3,961  (1)3,960 
Total cash equivalents and available-for-sale securities$254,565 $1 $(26)$254,540 $225,842 $30 $(16)$225,856 
Classified as:
Cash equivalents$110,077 $109,270 
Short-term investments144,463 116,586 
Total cash equivalents and available-for-sale securities$254,540 $225,856 
As of March 31, 2024 and December 31, 2023, all of our cash equivalents and short-term investments were available-for-sale and had contractual maturities of less than one-year. There were no other-than-temporary impairments on such securities.
5. Intangible Assets, net
The following table sets forth the major categories of intangible assets and the weighted-average remaining useful lives for those assets that are not already fully amortized or impaired:
March 31, 2024
(in thousands, except for in years)Remaining Useful Lives
(in years)
Gross Carrying AmountAccumulated AmortizationNet Carrying Amount
Distribution rights4.0$32,334 $(23,609)$8,725 
Total intangible assets$32,334 $(23,609)$8,725 
12

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
December 31, 2023
(in thousands, except for in years)Weighted-average Remaining Useful Lives
(in years)
Gross Carrying AmountAccumulated AmortizationAccumulated ImpairmentNet Carrying Amount
Distribution rights4.3$32,334 $(23,064)$ $9,270 
Internally developed technology(1)
1.58,918 (4,408)(3,972)538 
(1)
Acquired developed technology0.016,200 (6,525)(9,675) 
Customer relationships0.010,300 (7,940)(2,360) 
Total intangible assets$67,752 $(41,937)$(16,007)$9,808 
(1)During the three months ended March 31, 2024, we reclassified the $0.5 million net carrying amount of internally developed technology to “Non-current assets of discontinued operations” in connection with the discontinued operations presentation.
Amortization expense of the intangible assets in the table above were recorded on the condensed consolidated statements of operations and comprehensive loss based on the function of the associated asset. The detail breakdown of the amortization expenses on the condensed consolidated statements of operations and comprehensive loss were summarized as below:
 
Three Months Ended March 31, 2024
(in thousands)
Amortization of Intangible Assets (1)
Classified as Discontinued Operations (2)
Classified as Continuing Operations
Amortization
$545 $ $545 
Selling, general and administrative
528 (528) 
Research and development10 (10) 
Total amortization expense$1,083 $(538)$545 
 
Three Months Ended March 31, 2023
(in thousands)
Amortization of Intangible Assets (1)
Classified as Discontinued Operations (2)
Classified as Continuing Operations
Amortization$2,004 $(1,459)$545 
Selling, general and administrative1,737 (644)1,093 
Research and development261  261 
Total amortization expense$4,002 $(2,103)$1,899 
(1)Amount represents the amortization expense before the impact of reclassification for the discontinued operation presentation in the condensed consolidated statements of operations and comprehensive loss.
(2)Amount represents the reclassification for the current and prior periods for the discontinued operation presentation in the condensed consolidated statements of operations and comprehensive loss.
13

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Based on the amount of intangible assets as of March 31, 2024, the expected amortization expense for each of the next five fiscal years was as follows:
Year Ending December 31,(in thousands)
2024 remaining nine months$1,637 
20252,181 
20262,181 
20272,181 
2028545 
2029 and thereafter 
Total$8,725 
6. Inventories
Inventories consist of the following:
March 31,December 31,
(in thousands)20242023
Raw materials$4,049 $3,938 
Work in process21,109 17,418 
Finished goods25,122 24,223 
Total inventories$50,280 $45,579 

7. Accruals and other current liabilities
Accruals and other current liabilities consists of the following:
March 31,December 31,
(in thousands)20242023
Accruals related to:
Compensation(1)
$16,889 $30,267 
Inventories6,643 1,478 
Research and development6,544 5,173 
Selling, general and administrative6,276 9,019 
Royalty2,075 1,919 
Interest expense649 1,919 
Other current liabilities(1)
1,235 3,088 
Total accruals and other current liabilities$40,311 $52,863 
(1)Amounts related to current liabilities of discontinued operations have been reclassified to conform to current period presentation.

8. Leases
Operating Leases
Our operating leases primarily consist of non-cancellable facilities leases for research, manufacturing, and administrative functions. Our non-cancellable facilities operating leases have original lease periods expiring between 2027 and 2034, and include one or more options to renew for seven years to fourteen years. The monthly payments for our
14

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
operating leases escalate over the remaining lease term. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants.
ABPS Fill-And-Finish Line Lease
The ABPS Services Agreement contains a lease, which commenced in January 2022, related to a dedicated fill-and-finish line for the manufacturing of DAXXIFY® because it has an identified asset that is physically distinct for which we have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease provides us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity of the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line through our purchase orders to ABPS. Each party has the right to terminate the ABPS Services Agreement without cause, with an 18 month written notice to the other party. The lease is classified as a finance lease in the condensed consolidated balance sheets as of December 31, 2023 before the impact of a statement of work entered into in April 2024 as described below.
In February 2024, we entered into the second amendment to the ABPS Services Agreement, which extended the term of the ABPS Service Agreement through December 31, 2027, and modified our remedies with respect to conforming products and delays. In April 2024, we entered into a statement of work under the ABPS Service Agreement, and our minimum purchase obligation was established to be $25.1 million for the year ending December 31, 2024 pursuant to this statement of work. The minimum purchase obligation is subject to reduction based on ABPS’ actual manufacturing output. Due to the timing of the statement of work entered in April 2024, this lease was temporarily classified as an operating lease on March 31, 2024.
On March 31, 2024, the ABPS fill-and-finish line lease was reclassified from a finance lease to an operating lease on our condensed consolidated balance sheets. However, the lease activities during the three months ended March 31, 2024 were recorded based on finance lease accounting. Our operating and finance lease costs are summarized as follows:
 Three Months Ended March 31,
(in thousands)20242023
Finance lease:
Amortization of finance lease right-of-use asset (1)
$2,116 $2,318 
Interest on finance lease liability30 566 
Variable lease cost (2)
19 374 
Total finance lease costs2,165 3,258 
Operating leases:
Operating lease cost2,773 2,207 
Variable lease cost (3)
646 507 
Total operating lease costs3,419 2,714 
Total lease cost$5,584 $5,972 
(1)Amortization of the finance lease right-of-use asset started to be capitalized into inventories on the condensed consolidated balance sheets in the second quarter of 2023, as a result of the FDA approval of the PAS of the ABPS manufacturing facility.
(2)Variable finance lease cost includes validation, qualification, materials, and other related services which are not included in the lease liabilities and are expensed as incurred.
(3)Variable operating lease cost includes management fees, common area maintenance, property taxes, insurance and parking fees, which are not included in the lease liabilities and are expensed as incurred.
15

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
As of March 31, 2024, we have $0.4 million of accounts payable related to the fill-and-finish line lease under the ABPS Service Agreement. Additionally, we have maturities of our lease liabilities as follows:
(in thousands)
ABPS Fill-and-Finish Line Lease
Other Operating Leases
All Operating Leases
Year Ending December 31,
2024 remaining nine months$1,300 $7,063 $8,363 
2025 10,854 10,854 
2026 11,185 11,185 
2027 4,536 4,536 
2028 4,021 4,021 
2029 and thereafter 24,565 24,565 
Total lease payments1,300 62,224 63,524 
Less imputed interest(21)(17,564)(17,585)
Present value of lease payments$1,279 $44,660 $45,939 
Our lease contracts do not provide readily determinable implicit rates, as such, we used the estimated incremental borrowing rate based on the information available at the adoption, commencement, or remeasurement date. As of March 31, 2024, weighted-average remaining lease terms and discount rates are as follows:
ABPS Fill-and-Finish Line Lease
Other Operating Leases
All Operating Leases
Weighted-average remaining lease term (years)3.88.07.9
Weighted-average discount rate10.0 %10.0 %10.0 %
On March 31, 2024, the ABPS fill-and-finish line lease was reclassified from a finance lease to an operating lease on our condensed consolidated balance sheets. However, the lease activities during the three months ended March 31, 2024 were recorded based on finance lease accounting. Supplemental cash flow information related to the leases was as follows:
Three Months Ended March 31,
(in thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$2,555 $2,084 
Operating cash flows from finance lease$30 $566 
Financing cash flows from finance lease$4,227 $2,486 
Right-of-use assets obtained in exchange for lease liabilities
Finance lease$1,071 $23,735 
Lease Not Yet Commenced
PCI Supply Agreement
In April 2021, we entered into the PCI Supply Agreement pursuant to which PCI would serve as a non-exclusive manufacturer and supplier of DAXXIFY®. The initial term of the PCI Supply Agreement is dependent upon the date of regulatory submission for the manufacturing of DAXXIFY® and may be terminated by either party in accordance with the terms of the PCI Supply Agreement. The term of the PCI Supply Agreement may also be extended for one additional three-year term upon mutual agreement of the parties.
16

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
The PCI Supply Agreement contains a lease related to a dedicated fill-and-finish line and closely related assets for the manufacturing of DAXXIFY® because it has identified assets that are physically distinct for which we will have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease will provide us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity implied from the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line.
The embedded lease had not yet commenced as of March 31, 2024. The accounting commencement and recognition of the right-of-use lease assets and lease liabilities related to the embedded lease will take place when we have substantively obtained the right of control. The embedded lease is preliminarily classified as a finance lease.
Pursuant to the PCI Supply Agreement, we are responsible for certain costs associated with the design, equipment procurement and validation, and facilities-related costs, monthly payments and minimum purchase obligations throughout the initial term of the PCI Supply Agreement. As of March 31, 2024, we have made prepayments of $35.8 million to PCI which is recorded within “Finance lease prepaid expense” in the condensed consolidated balance sheets. Based on our best estimate as of March 31, 2024, our remaining minimum commitment under the PCI Supply Agreement is $13.8 million for 2024, $14.4 million for 2025, $18.8 million for 2026, $25.2 million for 2027, $29.1 million for 2028, and $134.5 million for 2029 and thereafter in aggregate.

9. Debt
The following table provides information regarding our debt:
March 31,December 31,
(in thousands)20242023
2027 Notes, non-current
$287,500 $287,500 
Less: Unamortized debt issuance costs(3,948)(4,279)
Carrying amount of the 2027 Notes283,552 283,221 
Notes Payable, current5,000 2,500 
Notes Payable, non-current145,000 147,500 
Less: Unamortized debt discount(2,425)(2,700)
Less: Unamortized debt issuance costs(1,289)(1,426)
Carrying amount of Notes Payable146,286 145,874 
Total debt$429,838 $429,095 
Interest expense relating to our debt in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:
Three Months Ended March 31,
(in thousands)20242023
Contractual interest expense$4,469 $3,383 
Amortization of debt issuance costs483 432 
Amortization of debt discount274 85 
Total interest expense$5,226 $3,900 
17

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Convertible Senior Notes
In February 2020, we issued the 2027 Notes, in the aggregate principal amount of $287.5 million, pursuant to the Indenture. The 2027 Notes are senior unsecured obligations and bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, began on August 15, 2020. The 2027 Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received $278.3 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs.
The 2027 Notes may be converted at any time by the holders prior to the close of business on the business day immediately preceding November 15, 2026 only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ending on June 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (iii) if we call any or all of the 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (iv) upon the occurrence of specified corporate events. On or after November 15, 2026 until the close of business on the second scheduled trading day immediately preceding the Maturity Date, holders may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.
The conversion rate will initially be 30.8804 shares of our common stock per $1,000 principal amount of the 2027 Notes (equivalent to an initial conversion price of approximately $32.38 per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the Maturity Date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event or notice of redemption, as the case may be.
Contractually, we could not redeem the 2027 Notes prior to February 20, 2024. We may redeem for cash all or any portion of the 2027 Notes, at our option, on or after February 20, 2024 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. The threshold to redeem has not been met as of March 31, 2024. No sinking fund is provided for the 2027 Notes.
If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
Capped Call Transactions
Concurrently with the 2027 Notes, we entered into capped call transactions with the option counterparties and used $28.9 million of the net proceeds from the 2027 Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the 2027 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a price cap of $48.88 of our common stock per share, which represents a premium of 100% over the last reported sale price of our common stock on February 10, 2020. The capped calls have an initial strike price of $32.38 per share, subject to certain adjustments, which corresponds to the conversion option strike price in the 2027
18

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Notes. The capped call transactions cover, subject to anti-dilution adjustments, approximately 8.9 million shares of our common stock.
The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the 2027 Notes. As the capped call transactions meet certain accounting criteria, the premium paid of $28.9 million was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of March 31, 2024 and December 31, 2023, we had not purchased any shares under the capped call transactions.
Note Purchase Agreement
In March 2022, we entered into the Note Purchase Agreement and issued the First Tranche in an aggregate principal amount for all such Notes of $100 million. In August 2023, we entered into the First Amendment to reduce the Second Tranche from $100 million to $50 million, and we subsequently issued $50 million to the Purchasers. Additionally, the First Amendment increased the uncommitted Third Tranche from $100 million to $150 million. The uncommitted Third Tranche was available until March 31, 2024, subject to the satisfaction of certain conditions set forth in the Note Purchase Agreement, including the achievement of greater than or equal to $50 million in trailing twelve months revenue for DAXXIFY® preceding the date of the draw request for the Third Tranche, and approval by Athyrium.
Our obligations under the Note Purchase Agreement are secured by substantially all of our assets and the assets of our wholly owned domestic subsidiaries, including their respective intellectual property.
The notes issued pursuant to the First Tranche and Second Tranche bear interest at an annual fixed interest rate equal to 8.50%. The First Amendment modified the variable interest rate adjustment for the Third Tranche from Adjusted Three-Month LIBOR to Adjusted Three-Month Term SOFR. If the Third Tranche of Notes Payable became committed, the Notes Payable would have born interest at an annual rate equal to the sum of (a) 7.0% and (b) Adjusted Three-Month Term SOFR for such interest period (subject to a floor of 1.50% and a cap of 2.50%). We are required to make quarterly interest payments on each Notes Payable commencing on the last business day of the calendar month following the funding date thereof, and continuing until the Maturity Date. Pursuant to the First Amendment, the Company is required to repay Athyrium the outstanding principal amount of the Second Tranche notes in installments on the last business day of each March, June, September and December (commencing in September 2024), in each case, based on the following principal amortization payment schedule: 2.5% in September and December 2024; 5.0% in March and June 2025; 7.5% in September and December 2025; and 10.0% in March and June 2026; followed by repayment of the Second Tranche in full on September 18, 2026. The Maturity Date may be extended to March 18, 2028 if, as of September 18, 2026, less than $90 million principal amount of our existing 2027 Notes remain outstanding and with the consent of the Purchasers. Initially, all principal for each tranche is due and payable on the Maturity Date. If any Third Tranche notes were issued, upon the occurrence of an Amortization Trigger (as defined in the Note Purchase Agreement), we would have been required to repay the principal of the Third Tranche in equal monthly installments beginning on the last day of the month in which the Amortization Trigger occurred and continuing through the Maturity Date. At our option, we may prepay the outstanding principal balance of all or any portion of the principal amount of the Notes Payable, subject to a prepayment fee equal to (i) a make-whole amount if the prepayment occurs on or prior to the first anniversary of the NPA Effective Date and (ii) 2.0% of the amount prepaid if the prepayment occurs after the first anniversary of the NPA Effective Date but on or prior to the second anniversary of the NPA Effective Date. Upon prepayment or repayment of all or any portion of the principal amount of the Notes Payable (whether on the Maturity Date or otherwise), we are also required to pay an exit fee to the Purchasers.
The Note Purchase Agreement includes affirmative and negative covenants applicable to us, our current subsidiaries and any subsidiaries we create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. We must also (i) maintain at least $30.0 million of unrestricted cash and cash equivalents in accounts subject to a control agreement in favor of Athyrium at all times (the Minimum Cash Covenant) and (ii) upon the occurrence of certain specified events set forth in the Note Purchase Agreement, achieve at least $70.0 million of Consolidated Teoxane Distribution Net Product Sales on a trailing twelve-months basis. The negative covenants include, among others, restrictions on our transferring collateral, incurring additional indebtedness, engaging in
19

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and undergoing a change in control, in each case subject to certain exceptions.
If we do not comply with the affirmative and negative covenants, such non-compliance may be an event of default under the Note Purchase Agreement. The Note Purchase Agreement also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 2.0% and would provide Athyrium, as administrative agent, with the right to exercise remedies against us and the collateral, including foreclosure against our property securing the obligations under the Note Purchase Agreement, including our cash. These events of default include, among other things, our failure to pay principal or interest due under the Note Purchase Agreement, a breach of certain covenants under the Note Purchase Agreement, our insolvency, the occurrence of a circumstance which could have a material adverse effect and the occurrence of any default under certain other indebtedness.
10. Stockholders’ Deficit and Stock-Based Compensation
2014 EIP
On January 1, 2024, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 3.5 million shares. For the three months ended March 31, 2024, 3.0 million shares of stock awards were granted under the 2014 EIP. As of March 31, 2024, 5.6 million shares were available for issuance under the 2014 EIP.
2014 IN
For the three months ended March 31, 2024, 0.2 million shares of stock awards were granted under the 2014 IN. As of March 31, 2024, 0.9 million shares were available for issuance under the 2014 IN.
HintMD Plan
For the three months ended March 31, 2024, no stock options or awards were granted under the HintMD Plan. As of March 31, 2024, 0.1 million shares were available for issuance under the HintMD Plan.
2014 ESPP
On January 1, 2024, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 0.3 million shares. As of March 31, 2024, 2.0 million shares were available for issuance under the 2014 ESPP.
Net Loss per Share
Our basic net loss per share from continuing operations is calculated by dividing the net loss from continuing operations by the weighted average number of shares of common stock outstanding for the period. Our basic net loss per share from discontinued operations is calculated by dividing the net loss from discontinued operations by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share from both continuing and discontinued operations are calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, shares of common stock underlying the 2027 Notes at the initial conversion price, outstanding stock options, unvested stock awards, and shares of common stock expected to be purchased under the 2014 ESPP, are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive.
20

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Common stock equivalents that were excluded from the computation of diluted net loss per share for both continuing and discontinued operations are presented below:
 March 31,
 20242023
Convertible senior notes8,878,9388,878,938
Unvested RSUs and PSUs5,496,0363,598,879 
Outstanding stock options3,669,8944,541,131
Unvested RSAs and PSAs642,4191,728,551
Shares of common stock expected to be purchased on June 30 under the 2014 ESPP220,451165,079
Follow-On Offering
In March 2024, we completed a follow-on offering, pursuant to which we issued 16.0 million shares of common stock at a price to the public of $6.25 per share (except with respect to 30,000 shares sold and issued to Mark Foley, our president, chief executive officer, and director, at $6.98 per share), for net proceeds of $97.1 million, after underwriting discounts and estimated offering costs.
ATM Offering Programs
On May 10, 2022, we entered into the 2022 ATM Agreement with Cowen. Under the 2022 ATM Agreement, we may sell up to $150.0 million of our common stock. We are not obligated to sell any shares under the 2022 ATM Agreement. Subject to the terms and conditions of the 2022 ATM Agreement, Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Market, to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. We pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights.
In 2023, we sold 3.2 million shares of common stock under the 2022 ATM Agreement at a weighted average price of $31.90 per share, resulting in net proceeds of $100.0 million after sales agent commissions and offering costs. No shares of common stock were sold during the three months ended March 31, 2024 from the 2022 ATM Agreement.
Stock-based Compensation Expense
The following table summarizes our stock-based compensation expense by line item in our condensed consolidated statements of operations and comprehensive loss:
(in thousands)
Three Months Ended March 31, 2024
Stock-based Compensation before Discontinued Operation Adjustments(1)
Classified as Discontinued Operations (2)
Classified as Continuing Operations
Selling, general and administrative
$7,624 $(240)$7,384 
Research and development
1,366 13 1,379 
Total stock-based compensation expense (exclusive of capitalized stock-based compensation expense)8,990 (227)8,763 
Capitalized stock-based compensation expense388  388 
Total stock-based compensation expense$9,378 $(227)$9,151 
21

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
(in thousands)
Three Months Ended March 31, 2023
Stock-based Compensation before Discontinued Operation Adjustments(1)
Classified as Discontinued Operations (2)
Classified as Continuing Operations
Selling, general and administrative
$10,265 $(710)$9,555 
Research and development
2,817 (1,420)1,397 
Total stock-based compensation expense (exclusive of capitalized stock-based compensation expense)13,082 (2,130)10,952 
Capitalized stock-based compensation expense1,407  1,407 
Total stock-based compensation expense$14,489 $(2,130)$12,359 
(1)Amount represents the stock-based compensation expense before the impact of reclassification for the discontinued operation presentation in the condensed consolidated statements of operations and comprehensive loss.
(2)Amount represents the reclassification for the current and prior periods for the discontinued operation presentation in the condensed consolidated statements of operations and comprehensive loss.
11. Fair Value Measurements
The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:
March 31, 2024
(in thousands)Fair ValueLevel 1Level 2Level 3
Assets
U.S. treasury securities$147,814 $147,814 $ $ 
Money market funds41,809 41,809   
U.S. government agency obligations8,431 8,431   
Commercial paper56,486  56,486  
Total assets measured at fair value$254,540 $198,054 $56,486 $ 
December 31, 2023
(in thousands)Fair ValueLevel 1Level 2Level 3
Assets
U.S. treasury securities$133,198 $133,198 $ $ 
Money market funds39,280 39,280   
U.S. government agency obligations3,960 3,960   
Commercial paper49,418  49,418  
Total assets measured at fair value$225,856 $176,438 $49,418 $ 

For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services.
The fair value of the 2027 Notes and the Notes Payable (Note 9) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We present the fair value of the 2027
22

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
Notes and the Notes payable for disclosure purposes only. As of March 31, 2024, and December 31, 2023, the fair value of the 2027 Notes was $211.5 million and $219.2 million, respectively. As of March 31, 2024 the fair value of the Notes Payable was approximately the same as its unamortized carrying value.
12. Commitments and Contingencies
Teoxane Agreement
In January 2020, we entered into the Teoxane Agreement, as amended, pursuant to which Teoxane granted us the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® dermal fillers, which include: (i) RHA® Collection of dermal fillers, and (ii) the RHA® Pipeline Products in the U.S. and U.S. territories and possessions, in exchange for 2,500,000 shares of our common stock and certain other commitments by us. The Teoxane Agreement is effective for a term of ten years from product launch in September 2020 and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. Our minimum purchase obligation for the year ending December 31, 2024 is $52 million. Our minimum purchase obligations after December 31, 2024 will be determined based on projected market growth rate. We are also required to meet certain minimum expenditure requirements in connection with commercialization and promotion of RHA® Collection of dermal fillers and RHA® Pipeline Products, which is $36 million for the year ending December 31, 2024. Minimum expenditures related to the commercialization and promotion of the RHA® Collection of dermal fillers and RHA® Pipeline Products after December 31, 2024 will be determined at a later date.
Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement.
Other Contingencies
As of March 31, 2024, we are obligated to pay BTRX up to a remaining $15.5 million upon the satisfaction of certain milestones relating to our product revenue, intellectual property, and clinical and regulatory events.
Indemnification
We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under other indemnification agreements is not determinable because it involves claims for indemnification that may be made against us in the future but have not been made. We have not yet incurred material costs to defend lawsuits or settle claims related to indemnification agreements.
We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
For the three months ended March 31, 2024 and 2023, no material amounts associated with the indemnification agreements have been recorded.
Litigation
In October 2021, Allergan filed a complaint against us and ABPS, one of our manufacturing sources of DAXXIFY®, in the U.S. District Court for the District of Delaware, alleging infringement of the following patents assigned and/or licensed to Allergan: U.S. Patent Nos. 11,033,625; 7,354,740; 8,409,828; 11,124,786; and 7,332,567. Allergan claims that our
23

REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
formulation for DAXXIFY® and ABPS’s manufacturing process used to produce DAXXIFY® infringes its patents. Allergan also asserted a patent with claims related to a substrate for use in a botulinum toxin detection assay. On November 3, 2021, we filed a motion to dismiss. On November 24, 2021, Allergan filed an amended complaint against us and ABPS, alleging infringement of an additional patent assigned and/or licensed to Allergan: U.S. Patent No. 11,147,878. On December 17, 2021, we filed a second motion to dismiss, and on January 14, 2022, Allergan filed an opposition to that motion. We filed a reply to Allergan’s opposition on January 21, 2022, and on August 19, 2022, the court denied our second motion to dismiss. On September 2, 2022, we filed an answer and counterclaims to Allergan's amended complaint. On December 30, 2022, Allergan filed a second amended complaint against us and ABPS, alleging infringement of three additional patents assigned and/or licensed to Allergan: U.S. Patent Nos. 11,203,748; 11,326,155; and 11,285,216. On January 20, 2023, we filed an answer and counterclaims to Allergan's second amended complaint. On March 3, 2023, we filed invalidity contentions, which challenge Allergan’s asserted patents. A Markman hearing was held on June 28, 2023, and a decision was issued on August 29, 2023. On September 15, 2023, U.S. Patent No. 7,332,567 was dismissed from the case with prejudice.

On December 10, 2021, a putative securities class action complaint was filed against the Company and certain of its officers on behalf of a class of stockholders who acquired the Company’s securities from November 25, 2019 to October 11, 2021, in the U.S. District Court for the Northern District of California. The complaint alleges that the Company and certain of its officers violated Sections 10(b) and 20(a) of Exchange Act by making false and misleading statements regarding the manufacturing of DAXXIFY® and the timing and likelihood of regulatory approval and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. The court appointed the lead plaintiff and lead counsel on September 7, 2022. The lead plaintiff filed an amended complaint on November 7, 2022. On January 23, 2023, we filed a motion to dismiss, and on March 30, 2024, the Court granted the motion with leave for the plaintiff to amend the complaint. On May 1, 2024, the plaintiff filed an amended complaint, which asserted similar claims to those in the prior complaint.

We dispute the claims in these lawsuits and intend to defend these matters vigorously. These lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcomes of the lawsuits are necessarily uncertain. We could be forced to expend significant resources in the defense of either lawsuit, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with each lawsuit.

We record a provision for a liability when we believe that it is both probable that a liability has incurred, and the amount can be reasonably estimated. As of both March 31, 2024 and December 31, 2023, no such provision for liabilities related to the above litigation matters were recorded on the condensed consolidated balance sheets.
24

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes appearing elsewhere in this Report and in conjunction with our other SEC filings, including our FY2023 Form 10-K.
This Report, including the documents incorporated by reference herein, contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Report and the documents incorporated by reference herein, including statements regarding our future financial condition, regulatory approvals, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. In addition, any statements that refer to our financial outlook or projected performance, profitability expectations, anticipated growth, milestone expectations, future expenses and cash flows, anticipated working capital requirements, market forecasts, capital expenditures, cash preservation plans, liquidity and financing requirements; our ability to comply with our debt obligations; our ability to sell stock under the 2022 ATM Agreement; our future financing plans and strategies; our future responses to macroeconomic and geopolitical factors; our ability to successfully commercialize and maintain regulatory approvals for DAXXIFY®; our ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to our drug product candidates and third-party manufacturers, including with respect to the PAS for the PCI manufacturing facility, DAXXIFY® for indications other than glabellar lines and cervical dystonia, and the RHA® Pipeline Products; our opportunity in therapeutics; our ability to secure and maintain favorable third party reimbursement for our Products; the process and timing of, and ability to complete, the current and anticipated future pre-clinical and clinical development of our product candidates including the outcome of such clinical studies and trials; development of an onabotulinumtoxinA biosimilar; the process and our ability to effectively and reliably manufacture supplies of DAXXIFY®; our ability to manufacture or receive sufficient supply of our Products in order to meet commercial demand; expectations regarding DAXXIFY® Zero-cost Inventory; our ability to successfully compete in the dermal filler and neuromodulator markets; the design of our clinical studies; the markets for our current and future products and services; our business strategy, plans and prospects, including our commercialization plans related to DAXXIFY® and the RHA® Collection of dermal fillers; the potential benefits of DAXXIFY®, the RHA® Collection of dermal fillers and our drug product candidates; the potential safety, efficacy and duration of DAXXIFY® for consumers and patients; our ability to maintain and seek out new strategic third-party collaborations to support our goals; consumer preferences related to our Products; the rate and degree of economic benefit, commercial acceptance, market, competition and/or size and growth potential of DAXXIFY®, the RHA® Collection of dermal fillers and our other drug product candidates, if approved; our ability to set a new standard in healthcare; the wind down of all activities related to the Fintech Platform; patent defensive measures; timing and expenses related to our ongoing litigation matters; our ability to defend ourselves in ongoing litigation; international expansion, including with respect to NMPA approval of DAXXIFY® for cervical dystonia and glabellar lines; anticipated milestone payments; our ability to expand our operations to support the commercialization of our Products and attract and retain qualified personnel to support our business; and our ability to comply with applicable laws and regulations; our ability to protect the Company from cybersecurity threats, including the impact of security failures and/or breaches; are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in Item 1A. “Risk Factors” and elsewhere in this Report and our FY2023 Form 10-K.
You should not rely upon forward-looking statements as predictions of future events. These forward-looking statements represent our estimates and assumptions only as of the date of this Report. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason to conform these statements to actual results or to changes in our expectations. You should read this Report, together with the information incorporated herein by reference, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
25

Summary of Risk Factors
Investing in our common stock involves risks. See Item 1A. “Risk Factors” in this Report and in our FY2023 Form 10-K for a discussion of the following principal risks and other risks that make an investment in Revance speculative or risky.
Our success as a company, including our ability to finance our business and generate revenue, and our future growth is substantially dependent on the clinical and commercial success of our Products. If we are unable to successfully commercialize our Products, complete the development and regulatory approval process of our product candidates, and maintain regulatory approval of our Products we may not be able to generate sufficient revenue to continue our business.

DAXXIFY® and any future product candidates, if approved, may not achieve market acceptance among injectors, HCPs, consumers and patients, and may not be commercially successful, which would adversely affect our operating results and financial condition.
We have incurred significant losses since our inception and we anticipate that we will continue to incur GAAP operating losses for the foreseeable future and may not achieve or maintain profitability in the future. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock, our ability to raise capital and our ability to maintain compliance with our debt covenants. We may require substantial additional funding to continue to operate our business and achieve our goals and a failure to obtain the necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.
DAXXIFY®, the RHA® Collection of dermal fillers and any future product candidates will face significant competition, including from companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, regulatory, manufacturing, marketing resources and expertise, greater brand recognition and more established relationships. Our failure to effectively compete may prevent us from achieving significant market penetration and expansion.
If we are not able to effectively and reliably manufacture DAXXIFY® or any future product candidates at sufficient scale and appropriate cost, including through any third-party manufacturers, as well as acquire supplies of the RHA® Collection of dermal fillers from Teoxane, our product development, regulatory approval, commercialization and sales efforts and our ability to generate revenue may be adversely affected.
We use third-party collaborators, including Teoxane, Viatris, Fosun, ABPS and PCI to help us develop, validate, manufacture and/or commercialize our products. Our ability to commercialize our products could be impaired or delayed if these collaborations are unsuccessful.
Macroeconomic and geopolitical factors and a public health crisis, such as the COVID-19 pandemic, have and may continue to adversely affect our business, as well as those of third-parties on which we rely for significant manufacturing, clinical or other business operations. They may also impact disposable income levels, which could reduce consumer spending and lower demand for our Products.
We are subject to uncertainty relating to pricing and reimbursement. Failure to obtain or maintain adequate coverage, pricing and reimbursement for DAXXIFY® for therapeutics uses, or our other future approved products, if any, could have a material adverse impact on our ability to commercialize such products. Even if coverage and reimbursement is provided, acceptance of any approved product may vary among HCPs, healthcare organizations and administrators and others in the healthcare community, which could impact our ability to realize a return on our investment and reduce demand for our products.
Reports of adverse events or safety concerns involving our Products could delay or prevent the Company or Teoxane from maintaining regulatory approval for such Products, or obtaining additional regulatory approval for additional indications or future product candidates. The denial, delay or withdrawal of any such approval would
26

negatively impact commercialization and could have a material adverse effect on our ability to generate revenue, business prospects, and results of operations.
Unfavorable publicity relating to one or more of our Products, whether related to aesthetic or therapeutic indications, may affect the public perception of our entire portfolio of Products.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results or actual consumer outcomes.
If our efforts to protect our intellectual property related to DAXXIFY®, the RHA® Collection of dermal fillers or any future product candidates are not adequate, we may not be able to compete effectively. Additionally, we are currently and in the future may become involved in lawsuits or administrative proceedings to defend against claims that we infringe the intellectual property of others and to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming and would have a material adverse effect on our ability to generate revenue if we are unsuccessful.
Servicing our debt, including the 2027 Notes and Notes Payable, requires a significant amount of cash to pay our substantial debt. If we are unable to generate sufficient cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive.
We are currently, and in the future may be, subject to securities class action and stockholder derivative actions. If other stockholder derivative actions, additional securities class actions or other lawsuits are brought against us, including product liability actions, and we cannot successfully defend ourselves, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources.
As our business and operations continue to grow, we may need to expand our development, manufacturing, regulatory, sales, marketing and distribution capabilities. If and when we expand such capabilities, we may encounter difficulties in managing our growth, which could disrupt our operations.
We have undertaken, and may in the future undertake, restructuring plans to adjust our investment priorities and manage our operating expenses, which plans may not result in the savings or operational efficiencies anticipated and could result in total costs and expenses that are greater than expected.

If we are not successful in discovering, developing, acquiring and commercializing additional product candidates other than our current Products, our ability to expand our business and achieve our strategic objectives may be impaired.
We have experienced and may experience in the future compromises or failures of our information technology systems or data, or those of third parties upon which we rely, which could adversely affect our business. Despite significant efforts to secure against such threats, it is impossible to entirely mitigate these risks.
Changes in and failures to comply with applicable laws, regulations and standards may adversely affect our business, operations and financial performance.
If we fail to attract and retain qualified personnel at all levels and functions, we may be unable to successfully execute our objectives.

27

Overview
Revance is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY® in China.
Recent Developments

Revance Aesthetics
For the three months ended March 31, 2024, we generated $51.7 million in revenue from the sale of our Products. As of March 31, 2024, we had over 7,500 aesthetic accounts.

DAXXIFY®
For the three months ended March 31, 2024 and 2023, we recognized $22.1 million and $15.4 million in net product revenue from the sale of DAXXIFY®, respectively. For the three months ended March 31, 2024, the DAXXIFY® aesthetic units sold increased by 105% and 7%, compared to the three months ended March 31, 2023 and December 31, 2023, respectively. For the three months ended March 31, 2024, our DAXXIFY® consumer coupon program, which functioned like a rebate, reduced product revenue by $2.0 million, which resulted in net product revenue of $22.1 million from the sale of DAXXIFY®.

RHA® Collection of Dermal Fillers
For the three months ended March 31, 2024 and 2023, we recognized $29.6 million and $30.3 million in product revenue from the sale of the RHA® Collection of dermal fillers, respectively.

In April 2024, the Company launched RHA 3® for injection into the vermillion body, vermillion border and oral commissure for lip augmentation and lip fullness in adults aged 22 years and older.

Revance Therapeutics
In May 2024, the Company expanded into the U.S. therapeutics market with the commercial launch of DAXXIFY® for the treatment of cervical dystonia. As of April 30, 2024, DAXXIFY® for the treatment of cervical dystonia had coverage for approximately 78% of commercial lives, which when combined with government coverage represents over 200 million lives.

Follow-On Offering
In March 2024, we completed a follow-on offering, pursuant to which we issued 16.0 million shares of common stock at a price to the public of $6.25 per share (except with respect to 30,000 shares which were sold and issued to Mark Foley, our chief executive officer and director, at $6.98 per share), for net proceeds of $97.1 million, after underwriting discounts and estimated offering costs.
Exit of the Fintech Platform Business
In September 2023, we commenced a plan to exit the Fintech Platform business as the costs and resources required to support the Fintech Platform no longer aligned with the Company’s capital allocation priorities. The exit and restructuring activities included elimination of Fintech Platform personnel, the termination of Fintech Platform research and development activities and an elimination of outside services expenses related to the Fintech Platform. Based on such plan, substantially all payment processing activities for Fintech Platform customers ended on January 31, 2024 and we substantially completed the activities related to winding down the remaining Fintech Platform operations as of March 31, 2024. Beginning as of March 31, 2024, the Service Segment is presented as a discontinued operation in our condensed consolidated financial statements
28

with certain prior period amounts retrospectively revised to reflect this change. Although we discontinued the Services Segment, we do not expect the discontinuation of the Services Segment to have a material effect on our liquidity going forward. See Part I, Item 1, “Financial Information—Notes to Condensed Consolidated Financial Statements (Unaudited)—Note 2 — Exit of the Fintech Platform Business” in this Report for additional information.
Results of Operations
In connection with the completion of exit of the Fintech Platform business discussed above, the results of our Fintech Platform business have been reflected as discontinued operations in our condensed consolidated financial statements as of and for the period ending March 31, 2024. Certain prior year figures were reclassified to conform to the current period presentation. Additionally, we began operating under a single reportable segment as of March 31, 2024. See Part I, Item 1, “Financial Information—Notes to Condensed Consolidated Financial Statements (Unaudited)—Note 2 — Exit of the Fintech Platform Business” in this Report for additional information. Accordingly, the results of operations discussed below no longer include a discussion of the Services Segment and the effect of the Services Segment on prior period amounts have been retrospectively revised for comparative purposes to more accurately reflect the period over period changes in our continuing operations.
Revenue
We generate product revenue from the sale of our Products. We generate collaboration revenue from an onabotulinumtoxinA biosimilar program with Viatris as well as the collaboration with Fosun for the development and commercialization of DaxibotulinumtoxinA for Injection. The service revenue generated from the Fintech Platform is classified as discontinued operations as discussed in Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —Note 2—Exit of the Fintech Platform Business”.
Product Revenue
Our breakdown of revenue by Product is summarized below:
Three Months Ended March 31,
(in thousands)20242023Change% Change
Product:
RHA® Collection of dermal fillers
$29,570 $30,280 $(710)(2)%
DAXXIFY®
22,149 15,378 $6,771 44 %
Total product revenue, net
$51,719 $45,658 $6,061 13 %
For the three months ended March 31, 2024, our product revenue from the sale of the RHA® Collection of dermal fillers decreased compared to the same period in 2023 primarily due to a decrease in units sold.
For the three months ended March 31, 2024, our product revenue from the sale of DAXXIFY® increased compared to the same period in 2023 primarily due to an increase in units sold, partially offset by a reduction in average selling price as a result of the new pricing introduced in September 2023 and the DAXXIFY® consumer coupon program, which functioned like a rebate that was offered in the first quarter of 2024. The rebate initiative resulted in approximately $2.0 million in contra revenue for the three months ended March 31, 2024.
Collaboration Revenue
We are actively developing an onabotulinumtoxinA biosimilar in collaboration with Viatris. As described in Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —Note 3—Revenue,” we generally recognize collaboration revenue for the onabotulinumtoxinA biosimilar program based on the determined transactions price of the contract multiplied by the quotient of the cost of development services incurred over the total estimated cost of development services for the expected duration of our performance
29

obligations. For the three months ended March 31, 2024, we recognized revenue related to development services under the Viatris Agreement of $0.2 million. For the three months ended March 31, 2023, no collaboration revenue was recognized from the biosimilar program.
We are also working with Fosun to develop and commercialize DaxibotulinumtoxinA for Injection in the Fosun Territory under the Fosun License Agreement. As described in Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —Note 3—Revenue,” we evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. For the three months ended March 31, 2024, no collaboration revenue is recognized from the Fosun License Agreement. For the three months ended March 31, 2023, $0.1 million was recognized from the Fosun License Agreement.

Operating Expenses
Operating expenses associated with the Fintech Platform business were classified as discontinued operations as discussed in Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —Note 2—Exit of the Fintech Platform Business”.
Three Months Ended March 31,
(in thousands, except percentages)20242023Change% Change
Operating expenses:
Cost of product revenue (exclusive of amortization)$14,911 $12,487 $2,424 19 %
Selling, general and administrative68,914 61,920 $6,994 11 %
Research and development14,393 17,532 $(3,139)(18)%
Amortization545 545 $— — %
Total operating expenses$98,763 $92,484 $6,279 %
Cost of product revenue (exclusive of amortization)
Three Months Ended March 31,
(in thousands, except percentages)20242023Change% Change
Cost of product revenue (exclusive of amortization)
Purchasing and manufacturing costs$13,461 $10,697 $2,764 26 %
Distribution, royalty and other fulfillment charges1,450 1,790 $(340)(19)%
Total cost of product revenue (exclusive of amortization)$14,911 $12,487 $2,424 19 %
Cost of product revenue (exclusive of amortization) is generally incurred when our Products are delivered and primarily consists of the purchasing cost of the RHA® Collection of dermal fillers and manufacturing costs of DAXXIFY® and distribution expenses, royalty, other fulfillment costs related to the RHA® Collection of dermal fillers and DAXXIFY®. Substantially all of DAXXIFY® manufacturing expenses incurred prior to DAXXIFY® GL Approval were classified as research and development expenses, resulting in Zero-cost Inventory.
Our cost of product revenue (exclusive of amortization) for the three months ended March 31, 2024 increased compared to the same period in 2023, which was primarily due to higher sales volume of DAXXIFY®. When Zero-cost Inventory, which is further discussed below, is depleted, we expect our cost of product revenue (exclusive of amortization) associated with DAXXIFY® to increase. We also anticipate that our cost of product revenue (exclusive of amortization) associated with the RHA® Collection of dermal fillers to increase as sales volume increases.
30

Purchasing and manufacturing costs
For the three months ended March 31, 2024, purchasing and manufacturing costs related to the RHA® Collection of dermal fillers and DAXXIFY® increased compared to the same period in 2023 primarily due to higher sales volume of our Products.
Distribution, royalty and other fulfillment charges
For the three months ended March 31, 2024, distribution, royalty and other fulfillment charges related to the RHA® Collection of dermal fillers and DAXXIFY® decreased compared to the same period in 2023 primarily due to a reduction in distribution implementation costs and other royalty expense related to DAXXIFY® launch.
Impact of Zero-cost Inventory for DAXXIFY®
If cost of product revenue (exclusive of amortization) included previously expensed inventories, the cost of product revenue (exclusive of amortization) for the three months ended March 31, 2024 and 2023 would have increased by approximately $6 million and $4 million, respectively. We expect to utilize existing Zero-cost Inventory until depleted in the near-term. Once depleted, we expect our cost of product revenue (exclusive of amortization) associated with DAXXIFY® to increase.

Selling, General and Administrative Expenses
 Three Months Ended March 31,
(in thousands, except percentages)20242023